Home > Boards > US OTC > Cannabis > Can B Corp. (CANB)

THE SIGNIFICANCE OF THE DEA LEGALIZATION & RESCHEDULING

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
sleekscape Member Profile
Member Level 
Followed By 823
Posts 29,697
Boards Moderated 1
Alias Born 03/16/14
160x600 placeholder
Current Report Filing (8-k) Edgar (US Regulatory) - 2/23/2021 7:05:02 AM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/16/2021 3:46:44 PM
Can B Corp. Accelerates its Innovations and Advancements at Pure Health Products InvestorsHub NewsWire - 2/16/2021 8:27:47 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 1/13/2021 3:17:46 PM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 12/30/2020 12:19:28 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 11/16/2020 3:22:51 PM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 10/15/2020 6:29:48 AM
Reflects Information That Constitutes a Substantive Change From or Addition to the Information Set Forth in the Last Offering... Edgar (US Regulatory) - 9/25/2020 6:02:27 AM
Small Company Offering and Sale of Securities Without Registration (d) Edgar (US Regulatory) - 9/22/2020 2:23:51 PM
Proxy Statement - Other Information (preliminary) (pre 14c) Edgar (US Regulatory) - 9/4/2020 3:43:45 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/4/2020 9:41:26 AM
Notification That Quarterly Report Will Be Submitted Late (nt 10-q) Edgar (US Regulatory) - 8/14/2020 4:43:34 PM
Notice of Qualification [regulation A] (qualif) Edgar (US Regulatory) - 8/10/2020 6:36:05 AM
Big Data Analytics Delivers During the Pandemic NetworkNewsWire - 6/30/2020 8:45:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/24/2020 9:03:01 AM
Registration a Offering Under the Securities Act of 1933 (1-a) Edgar (US Regulatory) - 6/3/2020 6:02:08 AM
Can B Corp Announces First Quarter 2020 Results Increased Quarterly Revenue, Outpacing Expense InvestorsHub NewsWire - 5/26/2020 7:29:34 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/20/2020 4:24:06 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/19/2020 6:04:12 AM
Notification That Quarterly Report Will Be Submitted Late (nt 10-q) Edgar (US Regulatory) - 5/14/2020 5:15:18 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/10/2020 1:07:33 PM
Can B Corp Update Regarding Stock Restructure InvestorsHub NewsWire - 3/6/2020 12:52:10 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/3/2020 4:47:53 PM
sleekscape Member Level  Sunday, 09/23/18 06:25:54 PM
Re: None
Post # of 27344 
THE SIGNIFICANCE OF THE DEA LEGALIZATION & RESCHEDULING OF CBD

We have a pair of historic catalysts that remain just ahead

I’ve written extensively about Mitch’s Hemp Farming Act of 2018 that is currently incorporated into The 2018 Farm Bill, so I’m going to dedicate this post to the DEA’s upcoming Legalization and Rescheduling of CBD


DEA LEGALIZATION (RESCHEDULING) OF CBD — within 24-48 hours

The DEA is forced to Reschedule CBD because on 6/25/18 the FDA approved Epidiolex (MJ-derived CBD) for clinical use — by law, they have 90 days from 6/25 to do so

Epidiolex has received approval for 2 indications thus far — Dravet Syndrome and Lennox-Gastaut Syndrome, both of which are congenital seizure disorders

The DEA is likely to move CBD from Schedule I to Schedule II/III/IV

Schedule V would be great, but I don’t think the DEA will go that far — it is simply too close to being unscheduled, which is exactly where the current data says it should be because it has not been reliably shown to have any significant potential for abuse nor dependence

But by placing CBD somewhere in the middle of the Schedule, the DEA is protecting big pharma and continuing to stymie progress in the medical acceptance of cannabis by not fully pulverizing the stigma of MJ as an addictive drug used predominantly for recreational purposes

So what’s so positive about the DEA moving CBD from Schedule I to Schedule II/III/IV?

Almost everything about it — please don’t misinterpret my skeptical view of the DEA’s treatment of cannabis and CBD with the historical importance and economic ramifications of this catalyst

By moving CBD from Schedule I, which means a substance has a high degree of abuse and dependence potential AND has zero medical value AND IS FEDERALLY ILLEGAL — Heroin and PCP are two examples of Schedule I Drugs — to Schedule II/III/IV (think many prescription anxiety/sleep aids) — CBD now moves from the category of illegal drug to a legal medicine with a low degree of abuse potential

The federal government is finally admitting that a constituent of cannabis, in this case the cannabinoid CBD, has bona fide medical value, which immediately differentiates it from stuck on Schedule I Medical Marijuana (THC + CBD)

The billion dollar question about the DEA’s legalization and rescheduling of CBD is as follows:

How will this impact the actual marketplace demand and acceptance (and perceptions of it) for CBD Oil Medical/Wellness Products?

My view is that it will have a very favorable effect overall

Insofar as garnering extensive media coverage and attention, the DEA’s Legalization and Rescheduling of CBD also has excellent potential

Therefore, the potential significance of this catalyst for the Medical CBD Oil subsector in general, and CANB in particular, is enormous


LEGALIZATION AND COMPLETE DESCHEDULING OF HEMP (INCLUDING CBD) VIA THE 2018 FARM BILL — within weeks

I will have a lot more to say about this moving forward, but suffice it to say that this will remove any and all lingering concerns regarding the Hemp & CBD Economy in America

CANB


Sleek


Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences